These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23537841)

  • 1. The effect of idursulfase on growth in patients with Hunter syndrome: data from the Hunter Outcome Survey (HOS).
    Jones SA; Parini R; Harmatz P; Giugliani R; Fang J; Mendelsohn NJ;
    Mol Genet Metab; 2013 May; 109(1):41-8. PubMed ID: 23537841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
    Burton BK; Whiteman DA;
    Mol Genet Metab; 2011 Jun; 103(2):113-20. PubMed ID: 21439875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
    Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
    Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene.
    Christianto A; Watanabe H; Nakajima T; Inazu T
    Clin Chim Acta; 2013 Aug; 423():66-8. PubMed ID: 23726270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
    Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M
    Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical response to long term enzyme replacement treatment in children, adolescent and adult patients with Hunter syndrome.
    Dalmau Serra J; Vitoria Miñana I; Calderón Fernández R; Cortell Aznar I
    Med Clin (Barc); 2015 Nov; 145(9):392-8. PubMed ID: 26360015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
    Burton BK; Jego V; Mikl J; Jones SA
    J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The natural history of growth in patients with Hunter syndrome: Data from the Hunter Outcome Survey (HOS).
    Parini R; Jones SA; Harmatz PR; Giugliani R; Mendelsohn NJ
    Mol Genet Metab; 2016 Apr; 117(4):438-46. PubMed ID: 26846156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of enzyme replacement therapy on linear growth in Korean patients with mucopolysaccharidosis type II (Hunter syndrome).
    Cho SY; Huh R; Chang MS; Lee J; Kwun Y; Maeng SH; Kim SJ; Sohn YB; Park SW; Kwon EK; Han SJ; Jung J; Jin DK
    J Korean Med Sci; 2014 Feb; 29(2):254-60. PubMed ID: 24550654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.
    Muenzer J; Jones SA; Tylki-Szymańska A; Harmatz P; Mendelsohn NJ; Guffon N; Giugliani R; Burton BK; Scarpa M; Beck M; Jangelind Y; Hernberg-Stahl E; Larsen MP; Pulles T; Whiteman DAH
    Orphanet J Rare Dis; 2017 May; 12(1):82. PubMed ID: 28464912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome.
    Polgreen LE; Thomas W; Orchard PJ; Whitley CB; Miller BS
    Mol Genet Metab; 2014 Feb; 111(2):101-6. PubMed ID: 24368158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome.
    Sohn YB; Cho SY; Lee J; Kwun Y; Huh R; Jin DK
    Mol Genet Metab; 2015 Feb; 114(2):156-60. PubMed ID: 25219292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
    Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
    Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of enzyme replacement therapy with idursulfase].
    Gutiérrez-Solana LG
    Rev Neurol; 2007 Feb; 44 Suppl 1():S7-S11. PubMed ID: 17345556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase.
    Barbier AJ; Bielefeld B; Whiteman DA; Natarajan M; Pano A; Amato DA
    Mol Genet Metab; 2013 Nov; 110(3):303-10. PubMed ID: 23988379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II.
    Schulze-Frenking G; Jones SA; Roberts J; Beck M; Wraith JE
    J Inherit Metab Dis; 2011 Feb; 34(1):203-8. PubMed ID: 20978944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.